Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
169, P. 115937 - 115937
Published: Nov. 25, 2023
Alveolar
epithelial
cell
(AEC)
senescence
is
considered
to
be
a
universal
pathological
feature
of
many
chronic
pulmonary
diseases.
Our
previous
study
found
that
epoxyeicosatrienoic
acids
(EETs),
produced
from
arachidonic
acid
(ARA)
through
the
cytochrome
P450
cyclooxygenase
(CYP)
pathway,
have
significant
negative
regulatory
effects
on
cellular
in
AECs.
However,
exact
mechanisms
by
which
EETs
alleviate
AECs
still
need
further
explored.
In
present
study,
we
observed
bleomycin
(BLM)
induced
enhanced
mitophagy
accompanied
increased
mitochondrial
ROS
(mito-ROS)
content
murine
alveolar
line
MLE12.
While
reduced
BLM-induced
and
mito-ROS
MLE12
cells,
mechanism
was
related
regulation
NOX4/Nrf2-mediated
redox
imbalance.
Furthermore,
inhibition
degradation
could
significantly
inhibit
regulate
NOX4/Nrf2
balance
exert
anti-oxidant
D-galactose-induced
premature
aging
mice.
Collectively,
these
findings
may
provide
new
ideas
for
treating
age-related
diseases
targeting
improve
dysfunction
reduce
oxidative
stress.
Cell Death Discovery,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: March 13, 2024
Abstract
Ferroptosis
is
an
iron
ion-dependent,
regulatory
cell
death
modality
driven
by
intracellular
lipid
peroxidation
that
plays
a
key
role
in
the
development
of
HCC.
Studies
have
shown
various
clinical
agents
(e.g.,
sorafenib)
ferroptosis
inducer-like
effects
and
can
exert
therapeutic
modulating
different
factors
pathway.
This
implies
targeting
tumor
may
be
very
promising
strategy
for
therapy.
In
this
paper,
we
summarize
prerequisites
defense
systems
occurrence
targets
drug-mediated
action
HCC,
differences
connections
between
other
programmed
deaths.
We
aim
to
theoretical
basis,
classical
inducers
research
progress
HCC
cells,
clued
treatment
regulating
network.
Further
investigation
specific
mechanisms
hepatocellular
carcinoma
interventions
at
stages
will
help
us
deepen
our
understanding
carcinoma,
with
view
providing
new
more
precise
preventive
as
well
measures
patients.
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
203, P. 107155 - 107155
Published: March 23, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
encompasses
hepatic
steatosis,
non-alcoholic
steatohepatitis
(NASH),
fibrosis,
cirrhosis,
and
hepatocellular
carcinoma.
It
is
the
primary
cause
of
chronic
disorders,
with
a
high
prevalence
but
no
approved
treatment.
Therefore,
it
indispensable
to
find
trustworthy
therapy
for
NAFLD.
Recently,
mounting
evidence
illustrates
that
Sirtuin
1
(SIRT1)
strongly
associated
SIRT1
activation
or
overexpression
attenuate
NAFLD,
while
deficiency
aggravates
Besides,
an
array
therapeutic
agents,
including
natural
compounds,
synthetic
traditional
Chinese
medicine
formula,
stem
cell
transplantation,
alleviates
NALFD
via
upregulation.
Mechanically,
NAFLD
by
reestablishing
autophagy,
enhancing
mitochondrial
function,
suppressing
oxidative
stress,
coordinating
lipid
metabolism,
as
well
reducing
hepatocyte
apoptosis
inflammation.
In
this
review,
we
introduced
structure
function
briefly,
summarized
effect
on
its
mechanism,
along
application
agonists
in
treating
Frontiers in Cell and Developmental Biology,
Journal Year:
2025,
Volume and Issue:
13
Published: Feb. 20, 2025
Liver
disease
is
a
significant
global
health
issue,
responsible
for
millions
of
deaths
annually.
Aging,
characterized
by
the
gradual
decline
in
cellular
and
physiological
functions,
impairs
tissue
regeneration,
increases
susceptibility
to
liver
diseases,
leads
health.
Silent
information
regulator
1
(SIRT1),
NAD⁺-dependent
deacetylase,
has
emerged
as
pivotal
factor
modulating
age-related
changes
liver.
SIRT1
preserves
function
regulating
essential
aging-related
pathways,
including
telomere
maintenance,
epigenetic
modifications,
senescence,
intercellular
communication,
inflammation,
mitochondrial
function.
Notably,
levels
naturally
with
age,
contributing
progression
increased
vulnerability
injury.
This
review
summarizes
regulatory
role
aging
its
impact
on
diseases
such
fibrosis,
alcoholic
associated
(ALD),
metabolic
dysfunction-associated
steatotic
(MASLD),
steatohepatitis
(MASH),
hepatocellular
carcinoma
(HCC).
We
also
discuss
emerging
therapeutic
approaches,
activators,
gene
therapy,
nutritional
interventions,
which
are
evaluated
their
potential
restore
mitigate
progression.
Finally,
we
highlight
future
research
directions
optimize
SIRT1-targeted
therapies
clinical
applications
conditions.
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
30(7), P. 652 - 662
Published: Feb. 21, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
affects
approximately
25%
of
the
world's
population
and
has
become
a
leading
cause
chronic
disease.
In
recent
years,
an
increasing
amount
data
suggests
that
MASLD
is
associated
with
aging.
As
ages,
age-related
will
major
global
health
problem.
Targeting
aging
new
approach
to
treatment
MASLD.
This
paper
reviews
current
studies
on
role
aging-related
factors
therapeutic
targets
in
MASLD,
including:
Oxidative
stress,
autophagy,
mitochondrial
homeostasis,
bile
acid
metabolism
dysbiosis.
The
aim
identify
effective
for
its
progression.
Circulation Research,
Journal Year:
2024,
Volume and Issue:
135(1), P. 222 - 260
Published: June 20, 2024
Cardiometabolic
disease
has
become
a
major
health
burden
worldwide,
with
sharply
increasing
prevalence
but
highly
limited
therapeutic
interventions.
Emerging
evidence
revealed
that
arachidonic
acid
derivatives
and
pathway
factors
link
metabolic
disorders
to
cardiovascular
risks
intimately
participate
in
the
progression
severity
of
cardiometabolic
diseases.
In
this
review,
we
systemically
summarized
updated
biological
functions
pathways
diseases,
mainly
focusing
on
heart
failure,
hypertension,
atherosclerosis,
nonalcoholic
fatty
liver
disease,
obesity,
diabetes.
We
further
discussed
cellular
molecular
mechanisms
pathway–mediated
regulation
diseases
highlighted
emerging
clinical
advances
improve
these
pathological
conditions
by
targeting
metabolites
factors.
